Supplementary Table 6 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Immune-mediated adverse events and clinically significant adverse events for lenvatinib by grade in cohort F
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Gastric Cancer Management and Outcomes
Colorectal Cancer Treatments and Studies
Publication details
- Publication date
- 26 March 2026
- Language
- EN